United States· US:59676-604_8d917bea-59a6-4338-b818-6ad5c62d02f9
ERLEADA
A apalutamide product containing apalutamide, registered in United States by Janssen Products, LP. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Apalutamide is registered in 15 of 19 countries.
Countries holding a registration under ATC L02BB05 (apalutamide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Apalutamide · ATC L02BB05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of apalutamide costs, country by country.
Normalised to the WHO defined daily dose (0.24 g), the median price runs from $0.094 in France to $370.27 in Switzerland — a ×3935 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Apalutamide · price per daily dose (0.24 g)
USD · FX 28 Sept 2026
- CH Switzerland$370.27
- FR France$0.094
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- APALUTAMIDE
- Manufacturer
- Janssen Products, LP
- Country
- United States (US)
- ATC code
- L02BB05
- ATC class
- Apalutamide
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- June 26, 2026
Packs & prices · 4
- ndc1159676-604-14
- ndc1159676-604-30
- ndc1159676604141 BLISTER PACK in 1 CARTON (59676-604-14) / 14 TABLET, FILM COATED in 1 BLISTER PACK
- ndc11596766043030 TABLET, FILM COATED in 1 BOTTLE (59676-604-30)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
670 interactions on record for apalutamide.
Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Apalutamide · interactions on record
670 records
- 244 severe
- 412 moderate
- 14 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- RolapitantA04AD14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Apalutamide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaERLEADAJanssen-Cilag International N.V., Beerse
- SpainERLEADA 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
- FinlandErleadaJanssen-Cilag International NV
- FranceERLEADA 240 mg, comprimés pelliculésJANSSEN CILAG INTERNATIONAL NV
- IrelandErleada 240 mg film-coated tabletsJanssen-Cilag International NV
- IcelandErleadaJanssen-Cilag International NV*
- NetherlandsErleada 240 mg filmomhulde tablettenJanssen-Cilag International NV
- NorwayErleadaJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Erleada
- Liechtenstein · Erleada
- Norway · Erleada
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0011dda9-d681-49ac-a343-a12af5efd102 GET /v1/drugs/0011dda9-d681-49ac-a343-a12af5efd102?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "240",
"substance": "APALUTAMIDE",
"productndc": "59676-604",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA210951",
"marketing_category": "NDA"
}See everything about apalutamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.